Atria Investments Inc Takes Position in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Atria Investments Inc purchased a new position in Anavex Life Sciences Corp. (NASDAQ:AVXL) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 13,300 shares of the biotechnology company’s stock, valued at approximately $76,000.

Several other institutional investors and hedge funds also recently made changes to their positions in AVXL. Vanguard Group Inc. increased its position in shares of Anavex Life Sciences by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 4,414,682 shares of the biotechnology company’s stock worth $22,471,000 after purchasing an additional 54,034 shares during the last quarter. Renaissance Technologies LLC grew its stake in Anavex Life Sciences by 483.8% in the second quarter. Renaissance Technologies LLC now owns 466,437 shares of the biotechnology company’s stock worth $1,968,000 after purchasing an additional 386,537 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Anavex Life Sciences by 17.1% in the second quarter. Bank of New York Mellon Corp now owns 280,556 shares of the biotechnology company’s stock valued at $1,184,000 after buying an additional 40,895 shares during the last quarter. Rhumbline Advisers raised its stake in Anavex Life Sciences by 15.8% during the second quarter. Rhumbline Advisers now owns 119,289 shares of the biotechnology company’s stock valued at $503,000 after buying an additional 16,293 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C bought a new position in Anavex Life Sciences during the 2nd quarter worth approximately $346,000. 31.55% of the stock is currently owned by hedge funds and other institutional investors.

Anavex Life Sciences Price Performance

Shares of NASDAQ AVXL opened at $9.11 on Monday. The firm has a market capitalization of $772.53 million, a PE ratio of -18.22 and a beta of 0.60. Anavex Life Sciences Corp. has a 1-year low of $3.25 and a 1-year high of $10.45. The business’s fifty day moving average price is $6.40 and its two-hundred day moving average price is $5.55.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Anavex Life Sciences in a report on Monday, November 4th.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.